Medical Imaging
| Call for proposals: | 2007 |
| Funding period: | 2008 - 2011 first phase |
| Funding volume: | Ca. 22.4 mio. EUR |
| Number of projects: | 9 networks with 34 subprojects overall |
1. Objectives of funding
With this funding measure the Federal Ministry of Education and Research (BMBF) would like to strengthen the application-oriented research in molecular imaging and support the advancement of already available approaches in view of promising clinical applications. For this purpose a close collaboration of different disciplines from the scientific, engineer-scientific and medical area as well as from academic and industrial research is necessary. With this funding the appropriate research groups as well as the available Know How and the available resources should be bundled up.
2. State of the funding measure
The projects are currently in conversion.
3. Funded projects
a) Short description of current projects
Network project: Smart Probes - Nanocapsule-based smatr probes for Optical Imaging of Prostate Cancer
Optical Imaging of Human Prostate (TP3)
|
Institut für Lasertechnologien in der Medizin |
|
|
Evaluation of nanocapsule-based imaging probes (TP2)
|
Universität Ulm |
|
|
Network project: EndoMed - Early detection of preneoplastic lesions and cancer in the stomach by molecular fluorescence endoscopy
Subproject 1: Preclinical evaluation of fluorescent biomarkers for early detection of preneoplasia and cancer in the stomach, parts of TP 3 and 4
|
Klinikum rechts der Isar der Technischen Universität München |
|
|
Subproject 2: Endoscopical instrumentation for optical molecular imaging in the stomach (ENDOMIS)
|
Karl Storz GmbH & Co. KG Tuttlingen |
|
|
Network project: Angiogenesis - Targeting for diagnosis and therapy
Subproject Universität Erlangen-Nürnberg
|
Friedrich-Alexander-Universität Erlangen-Nürnberg |
|
|
Subproject Universität Tübingen
|
Eberhard-Karls-Universität Tübingen |
|
|
Subproject MPI
|
Max-Planck-Institut für neurologische Forschung |
|
|
Network project: "CeTheProbes"
Design and Synthesis of Multifunctional Probes for Magnetic Resonance Imaging (TP1)
|
Eberhard-Karls-Universität Tübingen |
|
|
Incorporation of the enzyme-activated unit into the contrast agent and its in vivo evaluation" (TP2), Development of optimized vectors for the intracellular delivery of the contrast agent into cells - in vitro and in vivo evaluation (TP3)
|
Max-Planck-Institut für biologische Kybernetik |
|
|
In vivo imaging of cell differentiation after hematopoietic stem cell transplantation" (TP4) and in vivo determination of beta cell mass and function in diabetes (TP5)
|
Medizinische Hochschule Hannover |
|
|
Network project: NIMINI-MMRI
Target-specific contrast agents for magnetic resonance imaging of myocarditis in animal models
|
Capsulution Pharma AG |
|
Dr. Andreas Voigt |
New MR imaging technologies and methods for molecular imaging of myocarditis in animal models
|
MRB Forschungszentrum für Magnet-Resonanz-Bayern e.V. |
|
|
Histological, immunohistological and molecularpathological characterisation of myocardial inflammation in small animal models and correlation to molecular MR imaging
|
Eberhard-Karls-Universität Tübingen |
|
|
Clinical evaluation of molecular CMR contrast agents and comparative assessment of different magnetic resonance imaging sequences in humans with myocardial inflammation based on experience gained in animal models
|
Robert-Bosch-Krankenhaus GmbH |
|
|
Network project: NCFHEB - NorChlor-Fluor-HomoEpiBatidin (NCFHEB) - a potential positron emission tomography (PET) marker of early Alzheimer`s disease
|
Universität Leipzig |
|
|
|
ABX advanced biochemical compounds |
|
|
|
Forschungszentrum Jülich GmbH |
|
|
|
Institut für Interdisziplinäre Isotopenforschung e.V. (IIF) |
|
|
Network project: TOMCAT - A consortium working towards the development and refining of Tailored Magnetic Nanoparticles for Cancer Targeting
|
Universitätsklinikum Hamburg-Eppendorf |
|
|
|
Christian-Albrechts-Universität zu Kiel |
|
|
|
Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie (HPI) |
|
|
Network project: MOBITUM - Watching Tumor Biology by Molecular Imaging
Subproject TU München
|
Klinikum rechts der Isar der Technischen Universität München |
|
|
Network project ModularProbes: Structure-based design of modular NMR molecular probes for high-sensitive detection of metastases
Subproject 3
|
Universität Duisburg-Essen |
|
|
Subproject 2
|
Ruprecht-Karls-Universität Heidelberg |
|
|
Subproject 1 und 4
|
Universität Duisburg-Essen |
|
|
INUMAC
Network projekt: Imaging of Neuro Disease Using high field MR And Contrastophores (INUMAC)
|
Siemens Aktiengesellschaft |
|
|
|
Bruker BioSpin MRI GmbH |
|
|
|
Albert-Ludwigs-Universität Freiburg |
|
|
The goal of the Imaging of Neuro disease Using high field MR And Contrastophores Consortium “INUMAC” is to conduct research in the field of ultra-high-field magnetic resonance tomography and novel contrast agents for the diagnosis of neurological diseases.
The INUMAC project has been structured in three work packages, focusing on the following key objectives:
1. Investigate, innovative technologies for improved sensitivity, spatial, temporal, and spectral resolution for clinical MR systems via R&D on a whole body ultra high field 11.7 Tesla MR system
2. Evaluate and exploit novel approaches and concepts for various critical MR system components, such as new gradient concepts, parallel excitation and real-time scanning.
3. Perform discovery & preclinical development of targeted contrast agents for the diagnosis of Alzheimer disease, brain tumors and stroke.
Germany and France have a long-standing history in MR device engineering and a leadership position in the contrast media market. The cooperative program will be conducted by a consortium of industrial and academic partners composed of Siemens Medical Solutions (Erlangen), Guerbet S.A. (Aulnay sous Bois), Bruker BioSpin MRI GmbH (Ettlingen), University Freiburg, the Commissariat à l’énergie atomique (“CEA”, Paris) and Alstom MSA, all together covering key competencies, know-how and IP in essential positions and mandatory technologies in the described R&D fields.